Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07578142

AcceXible Speech-Based Screening for Depression and Anxiety in University Students (UAQ, Mexico)

Major depressive disorder (MDD) and anxiety are increasingly prevalent among university student populations, yet early detection remains reliant on psychometric instruments tied to diagnostic criteria (e.g., PHQ-9, GAD). Emerging evidence suggests that depression affects both the acoustic properties and content of speech, making speech analysis a promising candidate as a digital biomarker for early screening.

This study evaluates the validity of acceXible, a speech-based machine learning platform, for the detection and monitoring of depression and anxiety in the student population of the Universidad Autónoma de Querétaro, Mexico. AcceXible captures spontaneous speech through open-ended interview tasks and applies automated acoustic and linguistic analysis.

The primary objective is to evaluate the validity of the acceXible spontaneous speech analysis system for depression and anxiety screening, assessed against the PHQ and GAD scales as reference standards. Secondary objectives include examining associations between speech-derived variables and other study measures, evaluating participant engagement with digital mental health resources, assessing user satisfaction with the platform, and analyzing longitudinal changes in scores across follow-up assessments.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

16 year–25 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Universidad Autónoma de Querétaro

Querétaro City, Querétaro, Mexico

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provision of voluntary written informed consent
  • Age 16-25 years
  • Current enrollment at BUAP
  • Spanish language proficiency
  • Access to a mobile device with internet connectivity
  • Ability to understand and follow basic acceXible usage instructions

Exclusion criteria

  • Refusal to participate
  • Psychomotor agitation
  • Sensory impairment (visual or auditory)
  • Cognitive impairment

Treatment and study plan

AcceXible

Device

Speech analysis

Primary outcomes

  1. Diagnostic accuracy of acceXible for depression and anxiety screening

    Time frame: Baseline

    Sensitivity, specificity, and positive predictive value of the acceXible speech analysis system relative to validated Spanish-language versions of the PHQ-9 and GAD-7 as reference standards. Sensitivity is defined as the probability of correctly classifying a participant with abnormal scores; specificity as the probability of correctly classifying a non-affected participant; and positive predictive value as the probability that a participant flagged by acceXible truly meets criteria for depression or anxiety.

Study contacts

Contact information is provided by the study sponsor or research team.

Dra. Olga Patricia García Obregón

CONTACT

[email protected]

+52 442 192 1200 ext. 5322

Sponsors and collaborators

Lead sponsor

Accexible

Industry

Collaborators

  • Universidad Autónoma de Querétaro

Registry information

Official study title

Validación Del Sistema de Cribaje y de Seguimiento de Accexible Para depresión y Ansiedad en el Entorno Del Alumnado de la Universidad Autónoma de Querétaro

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
May 11, 2026
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.